Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

A tojás és a tápanyagokkal dúsított tojás rendszeres fogyasztásának hatása az ekcéma állapotára Szingapúrban

2026. november 10. frissítette: Jung Eun Kim, National University of Singapore

A tojás és a tápanyagokkal dúsított tojás rendszeres fogyasztásának hatása az ekcémás állapotra Szingapúrban ekcémás egyének

The study aims to assess the effects of daily consumption of nutrients-fortified eggs on eczema condition in Singapore individuals with eczema. The investigators hypothesize that egg consumption will improve eczema condition and nutrients fortified egg consumption will improve further improvements when compared to standard egg consumption in individuals with eczema

A tanulmány áttekintése

Részletes leírás

This is a double-blind, randomized, parallel study and all subjects will complete a 12-week study period. Subjects will be tasked to consume nutrients-fortified eggs and regular eggs daily for 12 weeks. After which, subjects are assessed for changes in carotenoid status, antioxidant and anti-inflammatory biomarkers, skin and eye health measurements, and other biomarkers of health.

Tanulmány típusa

Beavatkozó

Beiratkozás (Tényleges)

43

Fázis

  • Nem alkalmazható

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi helyek

    • Singapore
      • Singapore, Singapore, Szingapúr, 117550
        • Department of Food Science and Techonology, Block S13

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

21 év (Felnőtt)

Egészséges önkénteseket fogad

Igen

Tanulmányozható nemek

Összes

Leírás

Inclusion Criteria:

  1. English-literate and able to give informed consent in English
  2. Male and female participants, aged between 21 and 59 inclusive
  3. Healthy individuals with no underlying condition or on regular medication
  4. BMI between 18.5-25 kg/m2
  5. Mild to moderate severity of eczema, which will also be determined using our questionnaires during the screening visit

Exclusion Criteria:

  1. Significant change in body weight (3 kg or more) in the past 3 months
  2. Significant exercise pattern over the past 3 months defined as high-intensity exercise of more than 3 hours per week
  3. Known food allergy to eggs
  4. Taking dietary supplements which may impact the study results
  5. Having gastrointestinal disorders not suitable for the study
  6. Current smokers
  7. Consumes more than 2 alcoholic drinks per day i.e. one drink is defined as either 150ml of wine, 340ml of beer/cider, or 45ml of distilled spirit
  8. Taking lipid-lowering and blood pressure-controlling medications for less than 3 years
  9. Pregnant or lactating women, or planning to conceive in the next 6 months
  10. Unwilling to stop the medication of eczema during the study, either topical creams or oral medications
  11. Hierarchical link (professional and familial ties) with the research team members
  12. Participating in another clinical study
  13. Having blindness in one eye or more, eye diseases, retinal/lens/optical nerve surgery, or other eye conditions that may impact the study results
  14. Low-quality macular pigment optical density results were determined during the screening visit.

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Kezelés
  • Kiosztás: Véletlenszerűsített
  • Beavatkozó modell: Párhuzamos hozzárendelés
  • Maszkolás: Kettős

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Kísérleti: Regular egg with habitual diet

Each subject will be provide one-on-one dietary counselling and written instructions for each subject will be provided by a research dietitian and trained research staff.Subjects will also be provided with 2 regular egg/day for 12 weeks.

Consumption of regular egg with habitual diet

Kísérleti: Nutrient-fortified egg with habitual diet

Each subject will be provide one-on-one dietary counselling and written instructions for each subject will be provided by a research dietitian and trained research staff.Subjects will also be provided with 2 nutrient-fortified egg/day for 12 weeks.

Consumption of nutrient-fortified eggs with habitual diet

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Skin questionnaires - SCORing Atopic Dermatitis (SCORAD) Index
Időkeret: Week 0, week 3, week 6, week 9, week 12

SCORing Atopic Dermatitis (SCORAD) Index is a clinical tool used to assess the severity of atopic dermatitis (AD), also known as eczema. This index can estimate participants' body surface area affected by burns (extent - A: percentage of body surface area affected), Intensity (B: clinical signs are assessed and scored on a scale from 0 (absent) to 3 (severe)), Subjective Symptoms (C: itch, sleep disturbance are evaluated based on the participants' report over the past three days, each scored on a scale from 0 (no symptom) to 10(severe symptom)).

The SCORAD index is calculated using the following formula:

SCORAD=A/5+7B/2+C

Interpretation Mild atopic dermatitis: SCORAD < 25 Moderate atopic dermatitis: SCORAD 25-50 Severe atopic dermatitis: SCORAD > 50

Week 0, week 3, week 6, week 9, week 12
Skin questionnaires - Eczema Area and Severity Index (EASI) scoring system
Időkeret: Week 0, week 3, week 6, week 9, week 12

EASI evaluates the extent and severity of eczema in four body regions: the head and neck, the trunk, the upper limbs, and the lower limbs.

The EASI score ranges from 0 to 72, with higher scores indicating more severe eczema:

0: No eczema 1-7: Mild eczema 8-21: Moderate eczema 22-50: Severe eczema 51-72: Very severe eczema

Week 0, week 3, week 6, week 9, week 12
Skin questionnaires - Dermatology life quality index (DLQI)
Időkeret: Week 0, week 3, week 6, week 9, week 12

DLQI is a dermatology-specific instrument used to measure the impact of skin diseases on patients' quality of life. Which assessed disease impact, monitor treatment effectiveness, guide clinical decision-making.

Interpretation of Scores:

0-1: No effect on patient's life 2-5: Small effect on patient's life 6-10: Moderate effect on patient's life 11-20: Very large effect on patient's life 21-30: Extremely large effect on patient's life

Week 0, week 3, week 6, week 9, week 12
Skin measurement - eczema related
Időkeret: Week 0, week 3, week 6, week 9, week 12

Skin hydration - units arbitrary Corneometer®. Transepidermal water loss - units gram/hour. Sebum level - unit µg/cm2. Skin pH level - skin pH meter. Skin tape stripping: stratum corneum components assessed by immune dot blots

Week 0, week 3, week 6, week 9, week 12
Skin carotenoids status
Időkeret: Week 0, week 3, week 6, week 9, week 12

Skin carotenoids concentration can be measured by Resonance Raman Spectroscopy, unit is skin carotenoid score, higher score means optimal, lower score means poor condition of skin carotenoids.

Week 0, week 3, week 6, week 9, week 12
Blood carotenoids levels
Időkeret: Week 0, week 6, week 12

Blood carotenoids levels can be measured by High-Performance Liquid Chromatography, unit is μmol/L.

Week 0, week 6, week 12

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Eye health - Macular Pigment Optical Density
Időkeret: Week 0, week 3, week 6, week 9, week 12

A measurement of macular pigment of the eye using a heterochromatic flicker photometry device. The measurements are in arbitrary units.

Week 0, week 3, week 6, week 9, week 12
Eye health - Visual acuity
Időkeret: Week 0, week 3, week 6, week 9, week 12

Participants will read out letters on a ETDRS LogMAR chart at a fixed distance where letters becomes smaller as it goes down the chart. Tests results will be recorded in number of letters read, where the more letters the better the outcome.

Week 0, week 3, week 6, week 9, week 12
Eye health - Photostress recovery time
Időkeret: Week 0, week 3, week 6, week 9, week 12

An ophthalmoscope will be used to shine a light into the participants eye for 10 seconds, and participants will be required to read letters off a chart the moment their vision returns to normal. The faster the recovery time, the better the outcome. Units will be in seconds

Week 0, week 3, week 6, week 9, week 12
Visual function questionnaire 25
Időkeret: Week 0, week 3, week 6, week 9, week 12

A questionnaire to for participants to self-evaluate their perception of their current eye health based on general vision, ocular pain, near activities, distance activities, vision specific functions, driving, color vision and peripheral vision. The best possible score is 100 and worst possible score is 0.

Week 0, week 3, week 6, week 9, week 12
Concentration of tumour necrosis factor-α
Időkeret: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. Tumor necrosis factor-α results will be presented in ng/L according to the commercially available enzyme-linked immunosorbent assay kits.

Week 0, week 6, week 12
Concentration of interleukin-6
Időkeret: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. Interleukin-6 results will be presented in ng/L according to the commercially available enzyme-linked immunosorbent assay kits.

Week 0, week 6, week 12
Concentration of high-sensitivity C-reactive protein
Időkeret: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. High-sensitivity C-reactive protein results will be obtained and presented in mg/L by commercial lab testing.

Week 0, week 6, week 12
Concentration of fasting blood glucose
Időkeret: Week 0, week 6, week 12

Fasting blood glucose will be measured using commercial lab testing using participants' blood, units will be in mmol/L.

Week 0, week 6, week 12
Concentration of malondialdehyde
Időkeret: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. Analyses of malondialdehyde using commercially available enzyme-linked immunosorbent assay kits. Units for malondialdehyde will be in ng/L according to assay kit instructions.

Week 0, week 6, week 12
Concentration of 8-isoprostaglandin-F2α
Időkeret: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. Analyses of 8-isoprostaglandin-F2α using commercially available enzyme-linked immunosorbent assay kits. Units for 8-isoprostaglandin-F2α will be in µmol/L according to assay kit instructions.

Week 0, week 6, week 12
Concentration of insulin
Időkeret: Week 0, week 6, week 12

Fasting blood insulin will be measured using commercial lab testing using participants' blood, units in μU/L.

Week 0, week 6, week 12
Percentage of glycated hemoglobin
Időkeret: Week 0, week 6, week 12

Glycated hemoglobin will be measured using commercial lab testing from participant's blood, units in percent.

Week 0, week 6, week 12
Skin advanced glycation end products levels
Időkeret: Week 0, week 3, week 6, week 9, week 12

Measurement of skin advanced glycation end products level using a skin autofluorescence device, where participants wlll be instructed to place their forearm over the device and a light will be shone and a reading can be captured by detecting fluorescence. The results will be presented as arbitrary units.

Week 0, week 3, week 6, week 9, week 12
Blood advanced glycation end products levels
Időkeret: Week 0, week 3, week 6, week 9, week 12

Participants will have their blood drawn by medical professionals at the Occupational Health Clinic. The blood will be processed and stored. Measurements will be done using ultra-performance liquid chromatography coupled with mass spectrometry techniques to determine the levels of advanced glycation end products. Units will be in μg/mL.

Week 0, week 3, week 6, week 9, week 12

Egyéb eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Dietary assessment
Időkeret: Week 0, week 3, week 6, week 9, week 12

3-day food record will be used to assess participants' dietary intake for two weekdays and one weekend day before each clinical visit.

Week 0, week 3, week 6, week 9, week 12
Measurement of height
Időkeret: Week 0, week 3, week 6, week 9, week 12

Height will be measured using height-weight scale and units will be in cm.

Week 0, week 3, week 6, week 9, week 12
Measurement of blood pressure
Időkeret: Week 0, week 3, week 6, week 9, week 12

A blood pressure monitoring device available commercially will be used be to measure their systolic and diastolic blood pressure. Unit is mmHg.

Week 0, week 3, week 6, week 9, week 12
Measurement of weight
Időkeret: Week 0, week 3, week 6, week 9, week 12

Weight will be measured using height-weight scale and units will be in kg.

Week 0, week 3, week 6, week 9, week 12
Measurement of waist circumference
Időkeret: Week 0, week 3, week 6, week 9, week 12

Waist circumference will be measured using a measuring tape by a trained personnel, units in cm.

Week 0, week 3, week 6, week 9, week 12

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Nyomozók

  • Kutatásvezető: Jung Eun Kim, PhD, RD, National University of Singapore

Publikációk és hasznos linkek

A vizsgálattal kapcsolatos információk beviteléért felelős személy önkéntesen bocsátja rendelkezésre ezeket a kiadványokat. Ezek bármiről szólhatnak, ami a tanulmányhoz kapcsolódik.

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Tényleges)

2024. július 17.

Elsődleges befejezés (Tényleges)

2025. október 27.

A tanulmány befejezése (Tényleges)

2025. december 1.

Tanulmányi regisztráció dátumai

Először benyújtva

2024. április 7.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2024. június 10.

Első közzététel (Tényleges)

2024. június 12.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. november 16.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. november 10.

Utolsó ellenőrzés

2026. november 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Terv az egyéni résztvevői adatokhoz (IPD)

Tervezi megosztani az egyéni résztvevői adatokat (IPD)?

NEM

IPD terv leírása

The link between participants' information data and the code will be kept confidential by the NUS research team or a trusted third party. Research data and results will only be collated in its coded format. All research data collected will be retained for a minimum of 10 years following the NUS Research Data Management Policy.

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Nem

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel